De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review

Wu,Cheng‑Chia; Horowitz,David  P.; Deutsch,Israel; Rahmati,Rahmatullah; Schecter,Jordan  M.; Saqi,Anjali; Wang,Tony  J. C.

doi:10.3892/ol.2015.3836

De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review

Authors:
- Cheng‑Chia Wu
- David P. Horowitz
- Israel Deutsch
- Rahmatullah Rahmati
- Jordan M. Schecter
- Anjali Saqi
- Tony J. C. Wang
View Affiliations

Affiliations: Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA, Department of Otolaryngology‑Head and Neck Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA, Department of Medical Oncology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA
Published online on: October 27, 2015 https://doi.org/10.3892/ol.2015.3836
Pages: 141-149
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traditionally, head and neck squamous cell carcinoma (HNSCC) has been considered to be a relatively homogeneous disease. However, recent data have demonstrated that human papillomavirus (HPV)‑positive and HPV‑negative disease are two different clinical entities associated with different outcomes. Preclinical and clinical studies have reported a divergence in treatment strategies as well as prognostic outcomes for HNSCCs that are HPV‑positive versus HPV‑negative. The present study describes the case of a 52‑year‑old man who presented with stage IVB cT2N3M0 right tonsillar HPV‑positive squamous cell carcinoma. Induction chemotherapy with docetaxel, cisplatin and 5‑fluorouracil (TPF), followed by chemoradiation therapy with carboplatin and 70 Gray (Gy) radiation in daily fractions was recommended. The patient completed the TPF and carboplatin treatment; however, he was unable to tolerate the radiation course, receiving a final dose of 46 Gy. A 60‑day follow‑up right neck salvage dissection was subsequently performed. Despite having received a partial radiation treatment of 46 Gy, the patient had no pathological evidence of disease at 60 days post radiation treatment. Repeat positron emission tomography‑computed tomography at 32 months after the right neck dissection revealed no evidence of disease. The present study also discusses the current preclinical in vitro and in vivo targets for HPV‑positive HNSCC and the obstacles presented in advancing clinical treatment modalities. Previous preclinical models investigating radiation sensitivity have yielded mixed results. Thus, it is important to understand and establish representative preclinical models for studying HPV and HNSCC to improve clinical research and therapeutic development. This review may guide future understanding of the role of HPV in HNSCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Brana I and Siu LL: Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Ann Oncol. 23(Suppl 10): x178–x185. 2012. View Article : Google Scholar : PubMed/NCBI
4	Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 french head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
5	Tribius S, Ihloff AS, Rieckmann T, et al: Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know. Cancer Lett. 304:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
6	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). New York, NY: Springer-Verlag. 2010.
7	Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
8	Grégoire V, Ang K, Budach W, et al: Delineation of the neck node levels for head and neck tumors: A 2013 update, DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 110:172–181. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gandini S, Botteri E, Iodice S, et al: Tobacco smoking and cancer: A meta-analysis. Int J Cancer. 122:155–164. 2008. View Article : Google Scholar : PubMed/NCBI
10	Hashibe M, Brennan P, Benhamou S, et al: Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. J Natl Cancer Inst. 99:777–789. 2007. View Article : Google Scholar : PubMed/NCBI
11	Friedman JM, Stavas MJ and Cmelak AJ: Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol. 5:781–791. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chung CH and Schwartz DL: Impact of HPV-related head and neck cancer in clinical trials: Opportunity to translate scientific insight into personalized care. Otolaryngol Clin North Am. 45:795–806. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
14	O'Rorke MA, Ellison MV, Murray LJ, et al: Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. Oral Oncol. 48:1191–1201. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 29:4294–4301. 2011. View Article : Google Scholar : PubMed/NCBI
16	Stein AP, Saha S, Yu M, Kimple RJ and Lambert PF: Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol. 27:462–469. 2014. View Article : Google Scholar : PubMed/NCBI
17	Marur S, Lee JW, Cmelak A, et al: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). J Clin Oncol. 30(Suppl): ASCO Annual Meeting Abstract 5566. 2012.
18	Zur Hausen H: Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wang MB, Liu IY, Gornbein JA and Nguyen CT: HPV-Positive oropharyngeal carcinoma: A systematic review of treatment and prognosis. Otolaryngol Head Neck Surg. Jun 29–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
20	Jin L and Xu ZX: Recent advances in the study of HPV-associated carcinogenesis. Virol Sin. 30:101–106. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ramakrishnan S, Partricia S and Mathan G: Overview of high-risk HPV's 16 and 18 infected cervical cancer: Pathogenesis to prevention. Biomed Pharmacother. 70:103–110. 2015. View Article : Google Scholar : PubMed/NCBI
22	Vozenin MC, Lord HK, Hartl D and Deutsch E: Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity. Cancer Treat Rev. 36:629–636. 2010. View Article : Google Scholar : PubMed/NCBI
23	Jaboin JJ, Shinohara ET, Moretti L, et al: The role of mTOR inhibition in augmenting radiation induced autophagy. Technol Cancer Res Treat. 6:443–447. 2007. View Article : Google Scholar : PubMed/NCBI
24	Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
25	Blitzer GC, Smith MA, Harris SL and Kimple RJ: Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 88:761–770. 2014. View Article : Google Scholar : PubMed/NCBI
26	Snow AN and Laudadio J: Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol. 17:394–403. 2010. View Article : Google Scholar : PubMed/NCBI
27	Narisawa-Saito M and Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
28	Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 28:4142–4148. 2010. View Article : Google Scholar : PubMed/NCBI
29	Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ang KK and Sturgis EM: Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 22:128–142. 2012. View Article : Google Scholar : PubMed/NCBI
31	Perrone F, Suardi S, Pastore E, et al: Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res. 12:6643–6651. 2006. View Article : Google Scholar : PubMed/NCBI
32	Gupta AK, Lee JH, Wilke WW, et al: Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys. 74:928–933. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kamradt MC, Mohideen N and Vaughan AT: RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol. 77:177–182. 2000. View Article : Google Scholar : PubMed/NCBI
34	Liu S, Song L, Zhang L, Zeng S and Gao F: miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1. Biochem Biophys Res Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
35	Spanos WC, Nowicki P, Lee DW, et al: Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 135:1137–1146. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nagel R, Martens-de Kemp SR, Buijze M, et al: Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol. 49:560–566. 2013. View Article : Google Scholar : PubMed/NCBI
37	Rieckmann T, Tribius S, Grob TJ, et al: HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 107:242–246. 2013. View Article : Google Scholar : PubMed/NCBI
38	Arenz A, Ziemann F, Mayer C, et al: Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol. 190:839–846. 2014. View Article : Google Scholar : PubMed/NCBI
39	Kimple RJ, Smith MA, Blitzer GC, et al: Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 73:4791–4800. 2013. View Article : Google Scholar : PubMed/NCBI
40	Andrei G, Snoeck R, Piette J, Delvenne P and De Clercq E: Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. 10:523–531. 1998.PubMed/NCBI
41	Abdulkarim B, Sabri S, Deutsch E, et al: Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene. 21:2334–2346. 2002. View Article : Google Scholar : PubMed/NCBI
42	Sirianni NI, Wang J and Ferris RL: Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol. 41:423–428. 2005. View Article : Google Scholar : PubMed/NCBI
43	Pang E, Delic NC, Hong A, Zhang M, Rose BR and Lyons JG: Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int J Radiat Oncol Biol Phys. 79:860–865. 2011. View Article : Google Scholar : PubMed/NCBI
44	Fu YJ, Liu SX and Xian JM: Combination of adenovirus p16(INK4A) gene therapy and ionizing radiation for laryngeal squamous cell carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban. 35:209–211. 2004.(In Chinese). PubMed/NCBI
45	Coppock JD, Wieking BG, Molinolo AA, et al: Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia. 15:620–630. 2013. View Article : Google Scholar : PubMed/NCBI
46	Sørensen BS, Busk M, Olthof N, et al: Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother Oncol. 108:500–505. 2013. View Article : Google Scholar : PubMed/NCBI
47	Gubanova E, Brown B, Ivanov SV, et al: Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res. 18:1257–1267. 2012. View Article : Google Scholar : PubMed/NCBI
48	Brumbaugh KM, Otterness DM, Geisen C, et al: The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell. 14:585–598. 2004. View Article : Google Scholar : PubMed/NCBI
49	Vermeer DW, Spanos WC, Vermeer PD, et al: Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer. 133:120–129. 2013. View Article : Google Scholar : PubMed/NCBI
50	Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP Jr, et al: A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 19:667–674. 2012. View Article : Google Scholar : PubMed/NCBI
51	Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al: Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
52	Uva P, Lahm A, Sbardellati A, Grigoriadis A, Tutt A and de Rinaldis E: Comparative membranome expression analysis in primary tumors and derived cell lines. PLoS One. 5:e117422010. View Article : Google Scholar : PubMed/NCBI
53	Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, et al: Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res. 19:855–864. 2013. View Article : Google Scholar : PubMed/NCBI
54	Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE and Weichselbaum RR: Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 2:755–762. 1996.PubMed/NCBI
55	Mellin H, Friesland S, Lewensohn R, et al: Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse and survival. Int J Cancer. 89:300–304. 2000. View Article : Google Scholar : PubMed/NCBI
56	Schwartz SR, Yueh B, McDougall JK, Daling JR and Schwartz SM: Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 125:1–9. 2001. View Article : Google Scholar : PubMed/NCBI
57	Lindel K, Beer KT, Laissue J, Greiner RH and Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 92:805–813. 2001. View Article : Google Scholar : PubMed/NCBI
58	Weinberger PM, Yu Z, Haffty BG, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 24:736–747. 2006. View Article : Google Scholar : PubMed/NCBI
59	Ragin CC and Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer. 121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
60	Posner MR, Lorch JH, Goloubeva O, et al: Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol. 22:1071–1077. 2011. View Article : Google Scholar : PubMed/NCBI
61	Lassen P, Eriksen JG, Krogdahl A, et al: The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 100:49–55. 2011. View Article : Google Scholar : PubMed/NCBI
62	Marur S, D'Souza G, Westra WH and Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11:781–789. 2010. View Article : Google Scholar : PubMed/NCBI
63	National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Head and neck cancer. Version 1. 2015.Available at. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdfAccessed. September 13–2015
64	Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al: Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 105:175–201. 2013. View Article : Google Scholar : PubMed/NCBI
65	Coordes A, Lenz K, Qian X, Lenarz M, Kaufmann AM and Albers AE: Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status. Eur Arch Otorhinolaryngol. July 31–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
66	Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL, Lewis JS Jr and Wang X: A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer. 119:72–80. 2013. View Article : Google Scholar : PubMed/NCBI